newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

  • Immix Biopharma appointed Michael Grabow, former Senior Commercial Leader at Chimerix, as Chief Commercial Officer to lead U.S. launch & commercial buildout for NXC-201 in relapsed/refractory AL Amyloidosis.
  • Grabow previously led Go-To-Market Strategy & Launch of MODEYSO® at Chimerix, which was acquired by Jazz Pharmaceuticals for $935 million in 2025.
  • NXC-201 is a sterically-optimized BCMA-targeted CAR-T cell therapy being evaluated in the NEXICART-2 registrational study for relapsed/refractory AL Amyloidosis, a condition with no currently approved FDA therapies.
  • The FDA has awarded NXC-201 Regenerative Medicine Advanced Therapy (RMAT) status & Orphan Drug Designation (ODD), with the EMA also granting ODD in the EU.
  • Relapsed/refractory AL Amyloidosis affects approximately 37,270 U.S. patients in 2025, a patient population estimated to grow at 12% annually.
  • The U.S. AL Amyloidosis market is projected to reach $6 billion in 2025, up from $3.6 billion in 2017.
  • Grabow brings over 25 years of biopharmaceutical commercialization experience & has driven over 10 successful drug launches prior to joining Immix.
  • Immix Bio's lead candidate NXC-201 utilizes a "digital filter" to eliminate toxic light chains & is described by CEO Ilya Rachman as potentially the first approved therapeutic for this disease.